Home > Riviste > Journal of Neurosurgical Sciences > Fascicoli precedenti > Articles online first > Journal of Neurosurgical Sciences 2021 Aug 03

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Journal of Neurosurgical Sciences 2021 Aug 03

DOI: 10.23736/S0390-5616.21.05437-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Gliomagenesis is orchestrated by the Oct3/4 regulatory network

Tatyana N. IGNATOVA 1, 2, Hersh J. CHAITIN 3, Nickolay V. KUKEKOV 4, Oleg N. SUSLOV 5, Galina I. DULATOVA 1, Khalid A. HANAFY 2, Frank. D. VRIONIS 2

1 Department of Neurosurgery, Health Science Center, University of Tennessee, Memphis, TN, USA; 2 Marcus Neuroscience Institute, Boca Raton Regional Hospital and Florida Atlantic University, Boca Raton, FL, USA; 3 College of Medicine, Florida Atlantic University, Boca Raton, FL, USA; 4 Center for Neurobiology and Behavior, Department of Pathology, Columbia University College of Physicians and Surgeons, New York, NY, USA; 5 McKnight Brain Institute, Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, USA


PDF


Glioblastoma multiforme (GBM) is a lethal brain tumor characterized by developmental hierarchical phenotypic heterogeneity, therapy resistance and recurrent growth. Neural stem cells (NSCs) from human central nervous system (CNS), and glioblastoma stem cells from patient-derived GBM (pdGSC) samples and cultured in both 2D well-plate and 3D monoclonal neurosphere culture system (pdMNCS). The pdMNCS model shows promise to establish a relevant 3D-tumor environment that maintains GBM cells in the stem cell phase within suspended neurospheres. Utilizing the pdMNCS, we examined GBM cell-lines for a wide spectrum of developmental cancer stem cell markers, including the early blastocyst inner-cell mass (ICM)-specific Nanog, Oct3/4,B, and CD133. We observed that MNCS epigenotype is recapitulated using gliomasphere-derived cells. CD133, the marker of GSC is robustly expressed in 3D-gliomaspheres and localized within the plasma membrane compartment. Conversely, gliomasphere cultures grown in conventional 2D culture quickly lost CD133 expression, indicating its variable expression is dependent on cell-culture conditions. Critically, this experiment demonstrates incomplete differentiation of cytoskeleton microtubules and intermediate filaments (IFs) of patient derived cells, similar to commercially available GBM cell lines. Subsequently, in order to determine whether Oct3/4 it was necessary for CD133 expression and cancer stemness, we transfected 2D and 3D culture with siRNA against Oct3/4 and found a significant reduction in gliomasphere formation. These results suggest that expression of Oct3/4,Aand CD133 suppress differentiation of GSCs.


KEY WORDS: Gliomagenesis; Oct 3/4; CD133; 3D-Neurospheres

inizio pagina